Bispecifics ate CAR-T's lunch: a multiple myeloma debate

<p>In this episode, Bernie and Anthony are joined by Myeloma Man Manni Mohyuddin, MD to discuss the debate surrounding the treatment of first relapse in multiple myeloma. Should we be using CAR-T? Bispecifics? How does the new mezigdomide data from ASCO 2026 inform our practice? Listen in for a spicy discussion!</p><p><br></p><p>Articles discussed:</p><ul><li>Nature Reviews Commentary: <a href="https://www.nature.com/articles/s41571-026-01159-6"><u>https://www.nature.com/articles/s41571-026-01159-6</u></a></li><li>CARTITUDE-4: <a href="https://www.nature.com/articles/s41571-026-01159-6"><u>https://www.nature.com/articles/s41571-026-01159-6</u></a></li><li>MajesTEC-3: https://www.nejm.org/doi/full/10.1056/NEJMoa2514663 </li></ul><ul><li>MajesTEC-9: https://www.nejm.org/doi/abs/10.1056/NEJMoa2603870 </li><li>Control arms in multiple myeloma trials: https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2026020329/567836/Improving-Control-Arms-in-2026-U-S-Myeloma-Trials</li><li>Predictors for CAR T cell therapy-associated immune-related adverse events? https://pubmed.ncbi.nlm.nih.gov/41540109/</li><li>Dex prophylaxis for lymphocytosis: https://ashpublications.org/bloodadvances/article/10/10/3629/567462/Dexamethasone-prophylaxis-for-excessive-lymphocyte</li><li>Mezi-KD vs. KD ASCO 2026: https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA7506</li></ul>